What is Nilotinib?

Nilotinib (Nilotinib), formerly known as AMN107, is a new oral TKI that is rationally designed to overcome imatinib resistance in chronic myelogenous leukemia (CML). Due to its chemical structure, nilotinib exhibits anti-cancer activity in chronic myelogenous leukemia through its ability to selectively inhibit BCR-ABL autophosphorylation.

In Phase I and II studies, nilotinib achieved good tolerability and durable efficacy in adult patients with Ph+ CML who were resistant or intolerant to at least one prior therapy, including imatinib, which subsequently led to the approval of nilotinib for the treatment of patients with newly diagnosed chronic myelogenous leukemia or patients with imatinib-resistant/-intolerant chronic or accelerated phase chronic myelogenous leukemia. In addition to inhibiting BCR-ABL, nilotinib, similar to imatinib, also has potent activity against DDR, KIT, PDGFR, and colony-stimulating factor receptor-1 (CSF-1R) tyrosine kinase.

The original drug Nilotinib is marketed in China under the name Nilotinib and is covered by medical insurance, but reimbursement is limited to patients who meet the indications. SpecificationsThe price of 150mg*120 tablets per box may be around 9,000 yuan. The Indian version of Nilotinib is available overseas. The price of Nilotinib's original drug, 150mg*28 capsules per box, may be around RMB 1,000 (the price may fluctuate due to exchange rates). The ingredients of the original drug sold domestically and abroad are basically the same. Currently, there is no generic version of Nilotinib produced and launched. For more drug information and specific prices, please consult Yaode Medical Consultants.